Quarterly report · Q2

Period2023-12-01 → 2024-05-31
Filed2024-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥4.2bn2023-12-01 → 2024-05-31Cons.Net sales
Revenue¥8.6bn2022-12-01 → 2023-11-30Cons.Net sales (5-year summary)
Revenue¥4.2bn2022-12-01 → 2023-05-31Cons.Net sales
Operating income¥202m2023-12-01 → 2024-05-31Cons.Operating income
Operating income¥156m2022-12-01 → 2023-05-31Cons.Operating income
Ordinary income¥212m2023-12-01 → 2024-05-31Cons.Ordinary income
Ordinary income¥345m2022-12-01 → 2023-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥156m2022-12-01 → 2023-05-31Cons.Ordinary income
Profit before tax¥252m2023-12-01 → 2024-05-31Cons.Income before income taxes
Profit before tax¥155m2022-12-01 → 2023-05-31Cons.Income before income taxes
Net income (owners)¥193m2023-12-01 → 2024-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥256m2022-12-01 → 2023-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥121m2022-12-01 → 2023-05-31Cons.Profit loss attributable to owners of parent
Net income¥193m2023-12-01 → 2024-05-31Cons.Profit loss
Net income¥121m2022-12-01 → 2023-05-31Cons.Profit loss
Total assets¥8.0bnat 2024-05-31Cons.Assets
Total assets¥8.3bnat 2023-11-30Cons.Assets
Total assets¥8.0bnat 2023-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.3bnat 2024-05-31Cons.Liabilities
Total liabilities¥5.7bnat 2023-11-30Cons.Liabilities
Net assets / equity¥2.7bnat 2024-05-31Cons.Net assets
Net assets / equity¥2.6bnat 2023-11-30Cons.Net assets
Net assets / equity¥2.5bnat 2023-05-31Cons.Net assets (5-year summary)
Cash and deposits¥947mat 2024-05-31Cons.Cash and deposits
Cash and deposits¥1.0bnat 2023-11-30Cons.Cash and deposits
Cash & equivalents¥947mat 2024-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.0bnat 2023-11-30Cons.Cash and cash equivalents
Cash & equivalents¥999mat 2023-05-31Cons.Cash and cash equivalents
Cash & equivalents¥911mat 2022-11-30dCons.Cash and cash equivalents
Operating cash flow¥90m2023-12-01 → 2024-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥470m2022-12-01 → 2023-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥223m2022-12-01 → 2023-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥96m2023-12-01 → 2024-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥370m2022-12-01 → 2023-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥217m2022-12-01 → 2023-05-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥101m2023-12-01 → 2024-05-31Cons.Net cash provided by used in financing activities
Financing cash flow¥21m2022-12-01 → 2023-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥80m2022-12-01 → 2023-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥158.382023-12-01 → 2024-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥117.592024-03-01 → 2024-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥209.882022-12-01 → 2023-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥99.172022-12-01 → 2023-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.392023-03-01 → 2023-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio34.2%at 2024-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.6%at 2023-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio31.1%at 2023-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2023-12-01 → 2024-05-31¥187m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2023-12-01 → 2024-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-12-01 → 2024-05-31¥202m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2022-12-01 → 2023-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2022-12-01 → 2023-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2022-12-01 → 2023-05-31¥141m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2022-12-01 → 2023-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2022-12-01 → 2023-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2022-12-01 → 2023-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2022-12-01 → 2023-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-12-01 → 2023-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-12-01 → 2023-05-31¥156m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 480
ItemContextValueUnit
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-329000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-637000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration-25210000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration-68600000JPY
Increase decrease in provision for directors bonuses ope cfPrior1YTDDuration-11100000JPY
Increase decrease in provision for directors bonuses ope cfCurrentYTDDuration-10500000JPY
Increase decrease in provision for directors retirement benefits ope cfPrior1YTDDuration-26325000JPY
Increase decrease in provision for directors retirement benefits ope cfCurrentYTDDuration2718000JPY
Interest and dividends income ope cfPrior1YTDDuration-2588000JPY
Interest and dividends income ope cfCurrentYTDDuration-2617000JPY
Foreign exchange losses gains ope cfPrior1YTDDuration678000JPY
Foreign exchange losses gains ope cfCurrentYTDDuration-588000JPY
Interest expenses paid on loans and bonds ope cfPrior1YTDDuration8868000JPY
Interest expenses paid on loans and bonds ope cfCurrentYTDDuration9474000JPY
Loss on retirement of noncurrent assets ope cfPrior1YTDDuration1064000JPY
Loss on retirement of noncurrent assets ope cfCurrentYTDDuration2146000JPY
Loss gain on sales of investment securities ope cfPrior1YTDDuration-JPY
Loss gain on sales of investment securities ope cfCurrentYTDDuration-42660000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration193667000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration375010000JPY
Decrease increase in inventories ope cfPrior1YTDDuration150108000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-250730000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration-340818000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration-121917000JPY
Increase decrease in accrued consumption taxes ope cfPrior1YTDDuration67192000JPY
Increase decrease in accrued consumption taxes ope cfCurrentYTDDuration-103676000JPY
Other net ope cfPrior1YTDDuration-120768000JPY
Other net ope cfCurrentYTDDuration-116207000JPY
Subtotal ope cfPrior1YTDDuration251448000JPY
Subtotal ope cfCurrentYTDDuration123761000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration2588000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration2617000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-8811000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-9498000JPY
Income taxes paid ope cfPrior1YTDDuration-22027000JPY
Income taxes paid ope cfCurrentYTDDuration-27294000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration223197000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration89585000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-220908000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-143412000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-JPY
Purchase of intangible assets inv cfCurrentYTDDuration-428000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration-JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration44609000JPY
Other net inv cfPrior1YTDDuration3893000JPY
Other net inv cfCurrentYTDDuration3021000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-217015000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-96210000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration200000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration-JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-11-30pass
balance sheet identityconsolidated 2024-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-11-30pass
statement vs summary · net assetsconsolidated 2024-05-31pass
statement vs summary · net income attributable to parentconsolidated 2022-12-01/2023-05-31pass
statement vs summary · net income attributable to parentconsolidated 2023-12-01/2024-05-31pass
statement vs summary · operating cash flowconsolidated 2022-12-01/2023-05-31pass
statement vs summary · operating cash flowconsolidated 2023-12-01/2024-05-31pass
statement vs summary · revenueconsolidated 2022-12-01/2023-05-31pass
statement vs summary · revenueconsolidated 2023-12-01/2024-05-31pass
statement vs summary · total assetsconsolidated 2023-11-30pass
statement vs summary · total assetsconsolidated 2024-05-31pass